AR100310A1 - Moléculas para transporte de antígeno modular mejoradas y sus usos - Google Patents

Moléculas para transporte de antígeno modular mejoradas y sus usos

Info

Publication number
AR100310A1
AR100310A1 ARP150100974A ARP150100974A AR100310A1 AR 100310 A1 AR100310 A1 AR 100310A1 AR P150100974 A ARP150100974 A AR P150100974A AR P150100974 A ARP150100974 A AR P150100974A AR 100310 A1 AR100310 A1 AR 100310A1
Authority
AR
Argentina
Prior art keywords
molecules
imat
module
transportation
prevention
Prior art date
Application number
ARP150100974A
Other languages
English (en)
Inventor
Tammen Harald
Birte Reiche Dania
Rose Horst
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of AR100310A1 publication Critical patent/AR100310A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Insects & Arthropods (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Proteínas recombinantes (aisladas), también denominadas como moléculas MAT mejores (iMAT), que comprende al menos un módulo de translocación, al menos un módulo de direccionamiento y al menos un módulo del antígeno, donde al menos un residuo de cisteína se sustituye con un residuo de aminoácido diferente. Tales moléculas iMAT son útiles específicamente como vacunas, por ejemplo, para terapia y/o prevención de alergias y/o enfermedades infecciosas y/o prevención de transmisión de enfermedades infecciosas en equinos. También ácidos nucleicos que codifican tales moléculas de iMAT, correspondientes vectores y células o líneas celulares primarias. Reivindicación 12: La molécula iMAT de acuerdo con cualquiera de las reivindicaciones 1 a 11, caracterizada porque comprende, con preferencia consiste en, una o más de las secuencias de aminoácidos de acuerdo con las SEQ ID Nº 7, 8, 9, 10, 11, 12, 13, 14, 17, 20, 21, 22, 23.
ARP150100974A 2014-03-31 2015-03-31 Moléculas para transporte de antígeno modular mejoradas y sus usos AR100310A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14162575 2014-03-31

Publications (1)

Publication Number Publication Date
AR100310A1 true AR100310A1 (es) 2016-09-28

Family

ID=50433975

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150100974A AR100310A1 (es) 2014-03-31 2015-03-31 Moléculas para transporte de antígeno modular mejoradas y sus usos

Country Status (12)

Country Link
US (2) US9920101B2 (es)
EP (1) EP3125933B1 (es)
JP (1) JP6370398B2 (es)
KR (1) KR20160138283A (es)
CN (1) CN106132996B (es)
AR (1) AR100310A1 (es)
AU (1) AU2015239770B2 (es)
CA (1) CA2943690A1 (es)
EA (1) EA034692B1 (es)
MX (1) MX2016012840A (es)
TW (1) TWI705823B (es)
WO (1) WO2015150243A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015239770B2 (en) 2014-03-31 2020-07-02 Boehringer Ingelheim Vetmedica Gmbh Improved modular antigen transportation molecules and uses thereof
AU2016333474A1 (en) 2015-09-30 2018-03-22 Boehringer Ingelheim Vetmedica Gmbh Improved modular antigen transportation molecules and uses therof in animals
WO2019081625A1 (en) 2017-10-25 2019-05-02 Allero Therapeutics Bvba TREATMENT OF IMMUNE DISEASES BY ADMINISTRATION OF ANTIGEN-SPECIFIC FORMULATIONS
US20220047648A1 (en) * 2019-01-09 2022-02-17 Md Healthcare Inc. Nanovesicles derived from bacteria of genus rhodococcus, and use thereof
CN110343160A (zh) * 2019-07-26 2019-10-18 四川农业大学 黄粉虫ym47蛋白、其编码基因及应用
KR200491545Y1 (ko) 2019-10-29 2020-04-24 김용호 맞춤형 기능성 베개
KR200494146Y1 (ko) 2019-10-29 2021-08-12 김용호 맞춤형 기능성 베개

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
ES2152976T3 (es) 1993-02-26 2001-02-16 Immtech Internat Inc Proteina crp mutante, procedimientos y medios para su fabricacion y su utilizacion.
GB9825421D0 (en) 1998-11-19 1999-01-13 Isis Innovation Process for oxidising terpenes
JP3993035B2 (ja) 2001-07-19 2007-10-17 松下電器産業株式会社 データ記録方法、記録媒体、および再生装置
DK1408114T3 (da) * 2002-10-11 2007-05-07 Imvision Gmbh Modulære antigen-transporter molekyler (MAT-molekyler) til modulation af immunreaktioner, tilhörende konstrukter, fremgangsmåder og anvendelser
EP1440979B1 (en) * 2003-01-21 2005-10-19 BIOMAY Produktions- und Handels- Aktiengesellschaft Process for the preparation of hypoallergenic mosaic proteins
US20090117136A1 (en) 2003-04-24 2009-05-07 Imvision Gmbh Recombinant allergen
ATE461278T1 (de) 2003-05-07 2010-04-15 Chemo Sero Therapeut Res Inst Verfahren zur reinigung des modifizierten hauptallergens von milben
DE10359351A1 (de) 2003-12-16 2005-07-21 Merck Patent Gmbh DNA-Sequenz und rekombinante Herstellung von Gruppe-4 Majorallergenen aus Getreiden
WO2007065633A1 (en) * 2005-12-05 2007-06-14 Imvision Ag Modulation of the immune response by administration of intralymphatic transduction allergen (itag) -molecules
MX2010001779A (es) 2007-08-15 2010-07-06 Circassia Ltd Peptidos para vacunas.
UY31930A (es) * 2008-06-25 2010-01-29 Boheringer Ingelheim Pharma Kg Pestivirus atenuados recombinantes, en particular a csfv, bvdv o bdv atenuado recombinante
JP2011212008A (ja) * 2010-03-16 2011-10-27 Olympus Corp 蛍光タンパク質およびｐＨ測定方法
WO2012121395A1 (ja) 2011-03-09 2012-09-13 国立大学法人徳島大学 コレステロール依存性細胞溶解毒素の変異体及びそのddsへの利用
US9546200B2 (en) 2011-06-09 2017-01-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Peptide for protection of allergic respiratory disorders
AU2015239770B2 (en) 2014-03-31 2020-07-02 Boehringer Ingelheim Vetmedica Gmbh Improved modular antigen transportation molecules and uses thereof
AU2016333474A1 (en) 2015-09-30 2018-03-22 Boehringer Ingelheim Vetmedica Gmbh Improved modular antigen transportation molecules and uses therof in animals
CN107389010A (zh) * 2017-07-25 2017-11-24 爱佩仪中测（成都）精密仪器有限公司 提高三维测量仪器测量精度的支撑机构

Also Published As

Publication number Publication date
US20180170978A1 (en) 2018-06-21
MX2016012840A (es) 2017-05-09
CN106132996A (zh) 2016-11-16
US10919945B2 (en) 2021-02-16
EA201691981A1 (ru) 2017-03-31
WO2015150243A1 (en) 2015-10-08
CN106132996B (zh) 2020-10-09
TWI705823B (zh) 2020-10-01
TW201607554A (zh) 2016-03-01
US20150274790A1 (en) 2015-10-01
CA2943690A1 (en) 2015-10-08
US9920101B2 (en) 2018-03-20
EP3125933A1 (en) 2017-02-08
AU2015239770B2 (en) 2020-07-02
JP6370398B2 (ja) 2018-08-08
EP3125933B1 (en) 2022-05-18
JP2017510268A (ja) 2017-04-13
EA034692B1 (ru) 2020-03-06
KR20160138283A (ko) 2016-12-02
AU2015239770A1 (en) 2016-08-04

Similar Documents

Publication Publication Date Title
AR100310A1 (es) Moléculas para transporte de antígeno modular mejoradas y sus usos
CO2018012374A2 (es) Moléculas de anticuerpo para el tratamiento del cáncer
CY1122800T1 (el) Συνθεσεις του παραγοντα viii και μεθοδοι δημιουργιας και χρησης αυτων
CY1120103T1 (el) Κλιμακωσιμο συστημα παραγωγης λεντιικου φορεα, συμβατο με βιομηχανικες φαρμακευτικες εφαρμογες
MX2018011384A (es) Arn de replicacion en trans.
CA3062698A1 (en) Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
MY176332A (en) Multispecific antibody constructs
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
BR112016016658A2 (pt) proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão
MX2021010668A (es) Proteinas de fusion de citoquinas.
BR112019004711A2 (pt) receptores de antígeno quiméricos compreendendo domínios de fibronectina tipo iii específicos para bcma e usos dos mesmos
MX2018003850A (es) Moleculas de transporte de antigeno modular mejoradas y sus usos en animales.
EA201501080A1 (ru) Новое применение обладающих способностью проникать в клетку пептидных ингибиторов пути трансдукции сигнала jnk для лечения различных заболеваний
AR105822A1 (es) Análogos de insulina
AR100606A1 (es) Variantes de lipasas y polinucleótidos que las codifican
MX2020001282A (es) Polipeptidos que tienen actividad trehalasa y uso de los mismos en proceso de produccion de productos de fermentacion.
AU2017260426A1 (en) Engineered nucleases useful for treatment of hemophilia A
MX2014015667A (es) Uso de polipeptidos que tienen actividad proteasa en alimentos para animales y detergentes.
MX2015010078A (es) Uso de polipeptidos con actividad proteasa en alimentos para animales.
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
EA201691011A1 (ru) Последовательность модифицированного эндолизина el188
EA201691004A1 (ru) Последовательность модифицированного эндолизина kz144
PE20230343A1 (es) Peptidos que estimulan respuestas inmunitarias antitumorales
BR112015019719A2 (pt) Proteínas melhoradas de ligação ao tnf
AR102120A1 (es) Interferón modificado con inmunogenicidad reducida